nVerses Capital’s Tyra Biosciences TYRA Stock Holding History

nVerses Capital’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400	Closed	-$9.4K	–	837
2024 Q3	$9.4K	Buy	+400	New	+$8.4K	﹤0.01%	900

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

nVerses Capital's TYRA Position: Q4 2024 in Review

nVerses Capital sold out of Tyra Biosciences (TYRA) in Q4 2024, closing a stake of 400 shares — an estimated $9.4K sold.

nVerses Capital first reported a position in TYRA in Q3 2024 and held it in 1 quarter. The position peaked at $9.4K in Q3 2024. 113 funds tracked by Wall St. Rank hold TYRA as of Q4 2024.

nVerses Capital reported no remaining Tyra Biosciences position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 400 Tyra Biosciences shares in Q4 2024, an estimated $9.4K.
nVerses Capital first reported a position in Tyra Biosciences in Q3 2024 and held it in 1 quarter.
nVerses Capital's Tyra Biosciences position peaked at $9.4K in Q3 2024.
113 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.